Triasima Portfolio Management inc. Acquires Shares of 3,519 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Triasima Portfolio Management inc. acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 3,519 shares of the biopharmaceutical company’s stock, valued at approximately $2,507,000.

A number of other large investors also recently modified their holdings of the company. State Street Corp increased its position in shares of Regeneron Pharmaceuticals by 1.3% in the 3rd quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock valued at $5,153,603,000 after purchasing an additional 61,277 shares during the last quarter. International Assets Investment Management LLC grew its position in shares of Regeneron Pharmaceuticals by 86,013.3% in the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after buying an additional 879,916 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of Regeneron Pharmaceuticals by 1.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 673,261 shares of the biopharmaceutical company’s stock valued at $707,759,000 after buying an additional 11,499 shares during the last quarter. Swiss National Bank grew its position in shares of Regeneron Pharmaceuticals by 0.6% in the 3rd quarter. Swiss National Bank now owns 321,600 shares of the biopharmaceutical company’s stock valued at $338,079,000 after buying an additional 2,000 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. grew its position in shares of Regeneron Pharmaceuticals by 0.4% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 302,616 shares of the biopharmaceutical company’s stock valued at $215,562,000 after buying an additional 1,108 shares during the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $722.07 on Friday. Regeneron Pharmaceuticals, Inc. has a 1-year low of $642.00 and a 1-year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The firm has a 50 day simple moving average of $716.62 and a 200-day simple moving average of $913.59. The firm has a market cap of $79.35 billion, a PE ratio of 17.87, a P/E/G ratio of 1.60 and a beta of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 33.61% and a return on equity of 16.88%. The firm had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same quarter in the prior year, the business posted $11.86 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 10.3% compared to the same quarter last year. On average, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.75 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.49%.

Analyst Ratings Changes

REGN has been the topic of a number of recent analyst reports. Citigroup dropped their target price on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Royal Bank of Canada dropped their price objective on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a research note on Friday, November 1st. BMO Capital Markets dropped their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a research note on Tuesday. Truist Financial dropped their price objective on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a research note on Wednesday, January 8th. Finally, Bank of America restated an “underperform” rating and issued a $565.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $973.13.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.